Buparlisib + Sonidegib
Phase 2Terminated 0 views this week 0 watching💤 Quiet
Interest: 27/100
27
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Carcinoma, Basal Cell
Conditions
Carcinoma, Basal Cell, Recurrent Skin Cancer, Skin Neoplasms, Basal Cell Nevus Syndrome
Trial Timeline
Feb 1, 2015 → Jun 1, 2017
NCT ID
NCT02303041About Buparlisib + Sonidegib
Buparlisib + Sonidegib is a phase 2 stage product being developed by Novartis for Carcinoma, Basal Cell. The current trial status is terminated. This product is registered under clinical trial identifier NCT02303041. Target conditions include Carcinoma, Basal Cell, Recurrent Skin Cancer, Skin Neoplasms.
What happened to similar drugs?
20 of 20 similar drugs in Carcinoma, Basal Cell were approved
Approved (20) Terminated (1) Active (0)
Hype Score Breakdown
Clinical
12
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02303041 | Phase 2 | Terminated |
Competing Products
20 competing products in Carcinoma, Basal Cell